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Abstract 
Susceptibility to adverse drug reactions (ADRs), multimorbidity, and frailty are associated 
with human ageing, yet there is wide variation in the severity and age at which individuals 
are afflicted.  Identifying genetic markers of increased risk of this phenotype would help 
stratify individuals to specialist interventions.  Nuclear factor erythroid derived-2 like 2 
(Nrf2) regulates a cell’s response to stressors, including the expression of enzymes involved 
in drug-metabolism.  Its expression has been shown to decline in animal ageing models.  In 
this study we tested the hypothesis that Nrf2 gene transcription/translation decline in human 
ageing, and that single nucleotide polymorphisms (SNPs) in the Nrf2 gene are associated 
with increased ADR risk, multi-morbidity, and frailty in older people.  Gene expression and 
protein levels were measured in peripheral blood mononuclear cells (PBMCs) donated from 
healthy patients aged 18-80 years old.  Nrf2 genotypes were determined at three loci in a sub-
population of patients recruited to the PRIME study (a multicentre prospective cohort study 
that followed older adults for 8-weeks post-discharge to determine ADR).  Both Nrf2 gene 
and protein expression declined significantly with age in human PBMCs.  In the PRIME sub-
study population, the rs35652124 Nrf2 SNP was associated with increased ADR risk, and 
decreased frailty and multi-morbidity scores. 
 
Keywords 
 
Nuclear-factor erythroid 2 like; precision medicine; pharmacogenomics; geriatrics; ageing  
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1. Introduction 
Older people are the largest consumers of healthcare interventions and the recipients of the 
majority of prescribed medications.  As a population, they are characterized by 
multimorbidity, frailty, and polypharmacy, and suffer more adverse drug reactions (ADRs) 
requiring hospitalization than younger adults (1).  Recent studies have attempted to identify 
clinical and social predictors of this phenotype, notably multimorbidity, frailty, and an 
increased susceptibility to ADRs, in an attempt to build models to predict those in need of 
early, or specialist intervention.  For example, several tools have been developed which use 
clinical factors to identify older patients at risk of developing an ADR (2-4).  However, it is 
clear that clinical and social factors alone do not explain all variation in the populations 
studied. Uncertainty remains regarding why some individuals, with limited exposure to 
known risk factors, still develop marked multimorbidity, frailty and increased susceptibility 
to ADRs in old age. 
 
Oxidative stress is at the core of many theories of ageing (5).  Indeed, Reactive Oxygen 
Species (ROS) are thought to play a central role in the pathology of several age-related 
diseases such as Parkinson’s disease (6) and cognitive impairment (5, 7) where they are 
thought to disrupt signaling pathways and cause cellular damage.  Organisms have, however, 
evolved an elaborate system to protect against oxidative damage.  Under conditions of acute 
oxidative stress, the transcription factor Nuclear Factor (Erythroid Derived 2)-Like 2 (Nrf2) 
becomes activated and induces the expression of a myriad of antioxidant genes.  However, 
recent evidence from rodent models shows that the activity of Nrf2 declines with age, along 
with a decrease in downstream anti-oxidant protein levels (8), increasing susceptibility to 
age-related diseases and the signs of ageing (9-13).  What is particularly interesting is that 
Nrf2 not only induces the expression of antioxidant proteins, but also enzymes and 
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transporters involved in Phase I and II drug-metabolism, such as glutathione-s-transferase, 
and p-glycoprotein (14).    If a decline in Nrf2 activity is mirrored in human ageing, not only 
could this provide an explanation for increasing multi-morbidity and frailty, but also for the 
increased risk of ADR and altered pharmacokinetics seen in human ageing.  Interestingly, 
there is some emerging evidence that both the nuclear concentration of Nrf2 protein, and its 
activity are reduced with age in human bronchial epithelial cells (15).  Whether a reduction is 
Nrf2 levels during ageing is exhibited in other human cells types, and whether it is the cause 
of the ageing phenotype has yet to be elucidated. 
 
There are several Single Nucleotide Polymorphisms (SNPs) in the promoter region of the 
human Nrf2 gene which affect the expression of Nrf2 in vivo.  These SNPs have been shown 
to associate with specific age-related diseases, including Acute Lung Injury (16), impaired 
forearm vasodilator response (17), and Parkinson’s Disease (18).  We might hypothesize 
therefore, that in the context of an age-related decline in Nrf2, individuals possessing a 
variant allele may be more sensitive to the adverse effects of medicines, have a greater 
number of co-morbidities, and are frailer.  This explorative study therefore has two main 
aims: (1) to test for an age-related decline of Nrf2 transcription and translation in peripheral 
blood mononuclear cells (PBMCs), and (2) to establish whether common SNPs in the 
promoter region of the Nrf2 gene are associated with an increased susceptibility to ADRs, 
multimorbidity, and frailty in older individuals. 
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2. Methods 
2.1 Ethical approval 
Ethical approval was granted by the University of Brighton Tier 2 Research Ethics committee 
(CRECLHPS-16-063) and by the South Central – Berkshire B Research Ethics Committee 
(16/SC/0240). 
 
2.2 Changes to the expression of Nrf2 with age 
2.2.1 Participants 
A convenience sample of healthy individuals (volunteers), ≥ 18-years-old were recruited over 
an 8-month period from a population of University students and staff.  Participant’s age, 
gender, details of regular medicines used, details of chronic medical conditions, and smoking, 
alcohol and recreational drug taking behaviour were recorded.  Each participant donated 6 
mL blood.  To detect a medium to large effect size (Cohen’s f) of age on Nrf2 expression, 
with 80% power at a significance level of 0.05 we calculated the required sample size to be in 
the region of 80 participants. 
 
2.2.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from donated whole blood by density gradient centrifugation (Ficoll-
Paque Plus (GE Healthcare Life Sciences, UK)) within 4 hours of donation according to 
established protocols.  Isolated PBMCs were split into two microcentrifuge tubes for 
determination of Nrf2 gene and protein expression. 
 
2.2.3 Extraction of messenger RNA 
Messenger RNA (mRNA) was extracted from PBMC pellets within 2 hours of isolation using 
a RNeasy Mini Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer’s 
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instructions.  Extracted mRNA was immediately converted to cDNA using QuantiTect 
Reverse Transcriptase (Qiagen, Germany).  cDNA samples were then stored at -20oC until 
later analysis. 
 
2.2.4 Quantitative real time polymerase chain reaction (q-rtPCR) 
Quantitative real time polymerase chain reaction (q-rtPCR) was carried out using a Rotor-
Gene Q 5plex PCR machine (Qiagen, Germany).  Separate cDNA samples from each 
participant were mixed with SYBR green MasterMix (Qiagen, Germany) along with forward 
and reverse primers (Eurofins Genomics, Germany) for either Nrf2 (gene of interest), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18s ribosomal subunits (both 
housekeeping genes).  Each participant sample was run in duplicate.  Primer sequences are 
listed in Table 1.  The conditions for q-rtPCR were: initial denaturation 95oC for 15 mins, 
followed by 40 cycles at 94oC for 15 s, 55oC for 30 s, and 72oC for 30 s. 
 
The log abundance, and log fold change of Nrf2 was determined using the Matz analytical 
method (MCMC.qpcr package) (19) in the statistical software program R (20). 
 
2.2.5 Determination of Nrf2 protein levels in PBMC samples 
Expression of Nrf2 protein was carried out using enzyme-linked immunosorbent assay 
(ab207223; Abcam, UK).  Isolated PBMCs were suspended in lysis buffer, and then prepared 
for the assay according to the manufacturer’s instructions.  Absorbance was measured using 
an Elisa Plate Reader at a wavelength of 450 nm with a reference set at 665 nm. 
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2.3 Association of Nrf2 genotype / haplotype with adverse drug reactions, multimorbidity 
and frailty 
 
2.3.1 Participants and recruitment 
A subset of older patients who had recently participated in the PRIME study (4, 21) were 
invited to send a cheek-swab of genetic material to establish their genotype at three Nrf2 SNP 
loci (rs35652124, rs6706649 and rs6721961) and to provide consent for study co-ordinators 
to access participant data collected during the original PRIME study .  The PRIME study was 
a large multi-centre study investigating the incidence and cost-implications for medication-
related harm (including ADR) in older people 8 weeks post-hospital discharge.  Inclusion 
criteria were: (1) prior participation in the PRIME study.  Exclusion criteria were: (1) PRIME 
participants who measured <7/10 on the abbreviated mental test score (AMTS) during the 
PRIME study, or those who during a follow-up phone call were deemed to have insufficient 
capacity and (2) deceased following participation in PRIME study (as determined by 
examination of hospital electronic records). 
 
2.3.2 PRIME study participants and dataset 
The PRIME study recruited 1280 older adults at hospital discharge from 5 hospitals in 
England between 2013 to 2015 (21).  Patients were assessed for the presence of an ADR over 
an 8-week period by a senior pharmacist using the Narajo algorithm (22).   A frailty index 
was developed and internally validated (23) based on the Rockwood approach (24).  This 
index included 55 age-related deficits from multiple domains (e.g. morbidity, cognition, 
mood, strength and mobility, nutrition, daily function).  Each patient’s disease burden was 
calculated by (1) a summation of comorbidities and (2) calculating a Charlson Index score 
using established criteria (25). 
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2.3.2 Sample size 
In a study investigating the association of the -617 (rs6721961) single nucleotide 
polymorphism (SNP) with Acute Lung Injury, Marzec et al. (16) demonstrated the SNP to 
increase the odds of disease by approximately 6-fold.  If we consider the odds ratio of Nrf2 
SNPs on the ageing phenotype to be similar to this value, and if we assume the population 
ADR rate to be around 10%, then this equates to an effect size of w=0.280.  By setting the 
significance level to 0.05 and power to 0.8, we therefore estimated a suitable sample size to 
be 100 participants. 
 
2.3.3 Genotyping of genetic material 
Genomic DNA was extracted from donated cheek swabs (Isohelix SK-1S; Isohelix, UK) 
using DNeasy Blood and Tissue Kits (Qiagen, Germany).  Isolated gDNA was checked for 
purity using a Nanodrop® Lite Spectrophotometer (Sigma, UK), before storage at -20oC 
prior further analysis.  DNA deemed to be of insufficient quality or quantity was discarded 
(e.g., yield < 1 ng/microL and A260/A280 < 1.4). 
 
Isolated gDNA samples were amplified using HotStar Taq Mastermix Kit (Qiagen, Germany) 
with forward and reverse primers for the Nrf2 gene (Eurofins Genomics, Germany; Table 1).  
Polymerase Chain Reaction conditions were as follows: 95oC for 4 mins (initial 
denaturation), then 35 cycles of 95oC for 45 s, 56oC for 45s and 72oC for 45 s, followed by a 
final elongation step at 72oC for 10 mins. PCR products were sequenced by Sanger 
sequencing.  Genotype was determined by visual analysis of the electropherogram at the 
rs35652124, rs6706649 and rs6721961 loci. 
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2.4 Data and statistical analysis 
When testing for age-related changes to Nrf2 gene expression, participants were stratified in 
age categories (18-29, 30-39, 40-49, 50-59, 60-69, >70). Log abundance and log-fold change 
of Nrf2 as a function of age category were then analysed using the Markov Chain Monte 
Carlo (MCMC) analytical method described by Matz et al. (MCMC.qpcr R statistical 
package, 2013) (19).  The MCMC.qpcr package uses a generalised linear mixed model based 
on lognormal-Poisson error distribution, that is fitted using MCMC.  Data from the qPCR 
experiments (gene of interest, and house-keeping genes) were organised according to 
participant and age-category.  Results were tested for significance using a One-way ANOVA 
with Dunnet’s post-hoc correction for multiple comparisons.  The Changes in Nrf2 protein 
expression were compared between participants aged <30 and >30 years old using an 
unpaired Student’s t-test. 
 
Genotype and haplotype association studies across all ages were conducted using Haploview 
software (Broad Institute, www.broadinstitute.org/haploview).  The software uses  a two 
marker expectation maximisation (EM) algorithm to estimate the maximum-likelihood values 
of the four gamete frequencies (26), given as Chi2 with significance at 5%.  Odds ratios and 
95% confidence intervals were determined from 2x2 contingency tables for single gene or 
haplotype of interest in cases and controls.  Single gene association analyses were conducted 
on the whole cohort, and then on a sub-population of participants aged 65-79 years old.  
Mann-Whitney tests were used to test for significance in single gene association analyses as 
the data followed a non-Gaussian distribution.  
 
Data handling was conducted in Microsoft® Excel.  Descriptive statistics and statistical 
testing (Chi2, analysis of variance (ANOVA), Student’s t-test, Mann-Whitney U test and 
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post-hoc analyses) were carried out using Graphpad Prism for Mac Version 6.00 (Graphpad 
Software, La Jolla California, USA).  Sample and power analysis, and Monte Carlo Markov 
Chain q-rtPCR analysis were conducted in R (R Core team, 2014 (20)), using the ‘pwr’ and 
‘MCMC.qpcr’ packages respectively.  Statistical significance was accepted if p<0.05.  Data 
are presented as mean ± standard deviation unless indicated otherwise. 
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Results 
2.5 Changes to the expression of Nrf-2 with age 
2.5.1 Participant demographics 
A total of 55 healthy volunteers provided consent and were enrolled into this part of the 
study.  The median age was 30 years (range 18-75), with 25 male participants (45%).  
Twenty-two participants (40%) self-reported at least 1 chronic medical condition, with the 
same number taking at least 1 regular medication.  Seven participants reported smoking at 
least 1 cigarette regularly each week, and thirty-nine participants (71%) reported consuming 
alcohol regularly, with a median of 4.0 units consumed each week (range 0-16).  As might be 
expected, we found a significant relationship between age category and both the number of 
reported chronic medical conditions, and the number of regular medications taken by 
participants (Chi2 test, p<0.001 and p<0.01 respectively).  A breakdown of the sample 
characteristics according to age category is provided in Table 2. 
 
2.5.2 Nrf-2 gene expression changes with age 
Using the Markov Chain Monte Carlo analytical method described by Matz et al. (2013) 
(19), we found that the Log abundance of Nrf2 is significantly lower in those aged >70 
compared to all younger age groups (p<0.0001, One-way ANOVA with Dunnet’s post-hoc 
correction for multiple comparisons; Figure 1A).  Similarly, we found that the negative Log-
fold change in Nrf2 is significantly greater in the >70-year-old age-group compared to all 
other ages (p<0.0001, One-way ANOVA with Dunnet’s post-hoc correction for multiple 
comparisons; Figure 1B).  Despite recruiting fewer participants than our target sample size, 
post-hoc analysis revealed a larger than anticipated effect-size of f=0.64, and power (β-
1)=0.95. 
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2.5.3 Nrf-2 protein levels changes with age 
To test whether translation of the Nrf2 gene is reduced with age, we measured Nrf2 protein 
levels in PMBCs extracted from volunteers.  The reason for looking at both Nrf2 mRNA and 
protein levels is because the basal level of Nrf2 protein is determined by a combination of 
both proteasomal degradation of Nrf2 protein, and Nrf2 gene transcription / translation.  A 
decrease in Nrf2 protein levels coupled with a decrease in Nrf2 gene expression will tell us 
that the mechanism is primarily transcription related, whereas a reduction in protein levels 
without a decrease in gene-expression will suggest that the mechanism is translation / 
degradation related.   
 
Unfortunately, several protein samples were used up from our original sample of 55 which 
meant that we were unable to compare protein levels across our originally determined age-
categories (as several categories contained only single measurements).  Instead, we compared 
Nrf2 protein expression between volunteers aged <30 years old (n=9) to those aged >30 years 
old (n=9) in two equally sized groups.  We found that Nrf2 protein expression was 
significantly lower in the >30-year-old age-group compared to the younger group (0.065 ± 
SEM 0.013 vs. 0.033 ± SEM 0.006 AU in <30-year-old and >30-year-old respectively; 
p<0.05, unpaired Student’s t-test; Figure 1C), in line with changes observed in gene 
transcription.  
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2.6 Association of Nrf-2 genetic polymorphisms with characteristics of ageing 
2.6.1 Participant demographics 
In this part of the study we tested the hypothesis that in the context of an age-related decline 
in Nrf2 expression, individuals possessing a variant Nrf2 allele would show increased 
susceptibility to ADR, and greater multimorbidity and frailty.  One hundred and thirty-one 
older patients from a sub-population of the PRIME study provided consent and donated 
genetic material.  Four of the 131 patients were deemed to have insufficient capacity during a 
follow-up telephone call (i.e. they were unable to recall details of the study upon questioning) 
and were removed from the study.  Genetic material that was supplied by a further 15 patients 
was of unsatisfactory quality to allow further processing and so these individuals were also 
excluded from the study.  A total of 112/131 patients had their Nrf2 gene successfully 
sequenced and genotyped at all 3 loci.  Table 3 provides a description of the demographics of 
these 112 patients.  One SNP was found to be in Hardy-Weinberg equilibrium (rs6721961)1, 
but two, the rs35652124 and the rs6706649, deviated significantly from equilibrium 
(p<0.0001; Chi2 test).  The frequencies of the alleles for the three loci studied in the Nrf2 
promotor region are shown in Table 4.   
 
2.6.2 Adverse drug reactions 
3.2.4.1 Single gene associations 
The ADR rate across our study population (when classified as either definite, probable or 
possible on a modified Naranjo algorithm) was found to be 34% (38/112).  We found that 
there was a significantly higher frequency of ADRs in individuals who were homozygous for 
G at the rs35652124 locus, compared to those who were either heterozygous or homozygous 
for A (p<0.05, Chi2 test, n=112).  Tables 5 provides details of the numbers of the sub-
population of patients who developed an ADR during the original PRIME study according to 
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genotype. When a stricter definition is used to classify ADR (i.e. only definite/probable on 
the modified Naranjo algorithm) we found the association between ADR and genotype was 
lost (Table 5).  The ADR rate in the total population when this definition was used was found 
to be 19.6% (22/112).  No associations were found between ADR and genotype at the other 
two loci (rs6721961 or rs6706649). 
 
4.2.4.2 Haplotype associations 
Due to their close physical proximity on the genome, and the potential for these loci being in 
linkage disequilibrium, we thought that it would be of value to explore whether certain 
combinations of Nrf2 alleles were associated with ADR.  Using our stricter definition of 
ADR (probable/definite according to the Naranjo algorithm), we found that the CGA 
haplotype (rs6721961, rs35652124 and rs6706649 respectively) showed increased odds of 
ADR compared with other haplotypes (OR 12.9, CI 1.01-166.0; p=0.01, Chi2 test).  The wide 
confidence intervals reflect the fact that the haplotype concerned was rare (n=3) in our 
population sample. 
 
2.6.3 Multimorbidity 
2.6.3.1 Single allele associations 
We found a significant relationship between genotype at the rs35652124 locus and 
multimorbidity.  Patients that were homozygous for the A allele typically had more co-
morbidities than AG/GG individuals (3 [interquartile range 2-5] vs. 3 [interquartile range 1-
4], AA vs. AG/GG respectively; p<0.05, Mann-Whitney U test; Figure 1A).  However, we 
found no significant difference between median Charlson Index scores when comparing both 
genotypes across the entire age-range (1 [interquartile range 1-3] vs. 1 [interquartile range 0-
2], AA vs AG/GG respectively; p>0.05 Mann-Whitney U test; Figure 1A). 
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To probe the effect of age further, we split our cohort into two groups: those aged 65-79, and 
those aged >80.  The value of this approach is that it allows us to look at the >80-year-old 
group separately, as these individuals are a poorly studied age-group, typically referred to as 
the oldest-old, and who may have a different underpinning physiology to the ‘younger’ old.  
In doing so, we found that there was no difference in multi-morbidity between genotypes in 
the >80-year-old age group.  Interestingly however, individuals aged between 65-79 who had 
the AG/GG genotype had significantly fewer co-morbidities (3 [interquartile range 2-5] vs. 2 
[interquartile range 1-4] AA vs. AG/GG respectively; p<0.01, Mann-Whitney U test; Figure 
2A), and lower Charlson Index scores when compared to AA individuals (1.50 [interquartile 
range 1.00-2.75] vs. 1.00 [interquartile range 0.00-1.00] AA vs. AG/GG respectively; p<0.01, 
Mann-Whitney U test; Figure 2B).   
 
In addition to comparing the number of co-morbidities and Charlson Index scores across 
genotypes, we also performed association analyses comparing the numbers of individuals 
across each genotype with a score of ≥3 on the Charlson Index (a score of ≥3 corresponded to 
being in the 90th percentile of the sample population).  We found that in patients aged 65-79, 
those with the rs35652124 A allele showed increased odds of having a Charlson index score 
of ≥3 (OR 9.03 95%CI 1.16-70.2, p=0.0127).  This corresponds to a positive predictive value 
of 0.59 conditional on carrying an A allele.  This is compared to a priori probability of 
having ≥3 co-morbidities in the 65-79 age group (without knowledge of genotype) of 0.13.  
We found no relationship between the number of co-morbidities, or the Charlson Index score 
for either the rs6706649 or rs6721961 SNP. 
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2.6.3.2 Haplotype associations 
When we examined the 65-79 age-group, we found that the CGG haplotype is associated 
with lower odds of multimorbidity (a score of ≥3 on the Charlson Index ) compared to other 
haplotypes (OR 0.11, CI 0.01-0.87; p=0.01, Chi2 test).  No association was found in the ≥80-
year-old age group. 
 
2.6.4 Frailty 
3.2.3.1 Single gene associations 
We found that individuals carrying the G allele (AG/GG) at the rs35652124 locus had a 
significantly lower frailty score compared to homozygous A patients across the whole cohort 
(0.109 [interquartile range 0.073 to 0.161] vs. 0.091 [interquartile range 0.055 to 0.127] AA 
vs. AG/GG respectively; p<0.05, Mann-Whitney U test; Figure 2C).  As with the 
comparisons of multi-morbidity, the effect of this genotype appears to be enhanced when 
comparing patients aged between 65-79 years old (0.107 [interquartile range 0.072 vs. 0.163] 
vs. 0.074 [interquartile range 0.036 to 0.108] AA vs. AG/GG; p<0.05, Mann-Whitney U test; 
Figure 2C).  No significant relationship was found in the ≥80-year-old group between frailty 
score and rs35652124 genotype.  No significant relationship was found between either the 
rs66706649 or rs6721961 genotype and frailty score. 
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3. Discussion 
To our knowledge, this is the first human s yestudy to show an association between a single 
nucleotide polymorphism in the Nrf2 gene and characteristics of the ageing phenotype.  It is 
also the first to show an age-related decrease in both Nrf2 gene, and protein expression in 
PBMCs of human volunteers.  Nrf2 gene expression appears to decline late in life, whereas a 
decline in Nrf2 protein expression potentially precedes this.  Further work is necessary to 
build on these observations to understand the mechanism and precise chronology behind 
these events. Together, these data may be useful in the design of tools that enable risk 
stratification of patients as they enter old age. This personalised approach is in line with a 
common agenda of using genetic and bio-psychosocial determinants to individualise 
treatment options to older people across Europe (27).  However, due to the relatively small 
sample size of this study, and the limited diversity of its participants, further work in this area 
should be conducted to demonstrate the generalisability of these findings.  
 
Our interest in investigating the role that this gene plays in multi-morbidity, frailty and 
susceptibility to ADRs stemmed from its important regulatory effect on a number of key anti-
oxidant and xenobiotic response genes.  There is a substantial amount of evidence that 
oxidative stress is a contributory factor in the ageing process of certain tissues / organ 
systems (5).  Specifically, recent work shows that oxidative stress (induced by mutations to 
superoxide dismutase) is strongly correlated with frailty in mice (28).  Furthermore, there is 
evidence in humans that frailty is associated with lower expression of stress response genes 
including Nrf2, and superoxide dismutase-2 (29).  Interestingly, it is known that oxidative 
stress can trigger the release of a cocktail of pro-inflammatory cytokines and chemokines 
which, on a chronic time-scale, may lead to inflammageing – a condition that is associated 
with frailty and cardiovascular disease (30).  A reduction in Nrf2 expression with age, 
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coupled with a polymorphism which decreases the gene’s expression may therefore lead to 
signs and symptoms of ageing (e.g. frailty) and an increased risk of developing an ADR due 
to decreased downstream phase I and phase II enzyme expression.   
 
The three SNPs that we investigated in this study are all found in the promoter region of the 
Nrf2 gene (16, 31).  Both the rs6721961 (-617) and rs6706649 (-651) minor alleles (C→A, 
and G→A respectively) have consistently been shown in vitro to reduce the expression of 
Nrf2 (16, 32); we might therefore expect to see the strongest phenotypic associations with 
these particular variants.  However, no significant associations were found between the minor 
alleles at these two loci and any of our outcome measures.  One possible reason for this may 
be the low frequency of minor alleles observed in our cohort at these two loci, which limits 
the variation in our sample population.  It is interesting to note that the minor allele frequency 
(MAF) of the rs6721961 was substantially lower than those observed in 3 recent studies 
(4.0% in our study vs. 31.2, 24.4, and 12.9%, by Song, Yu and Ran et al. (32-34)).  The MAF 
at rs6706649 locus was however in line with those observed previously at approximately 
5.4%.  It should also be noted that the observed genotype frequencies at both the rs6706649 
and the rs35652124 loci deviated significantly from Hardy-Weinberg equilibrium.  There are 
a number of possible explanations for this, however, the most likely is that our sample 
population consisted of a number of smaller sub-populations.  Indeed, it appears that the 
deviation of our observed genotype frequencies from the expected frequencies reaches 
significance at the rs6706649 locus because of one extra individual with the rare AA 
genotype.  Similarly, at the rs35652124 locus, significant deviation from Hardy-Weinberg 
equilibrium appears to have been achieved by an extra 3 heterozygotes (who were expected 
to have been AA, and 2 x GG).    
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In contrast to the rs6271961 and rs6706649 SNPs, the rs35652124 locus did show an 
association with our various outcome measures.  For example, we observed an association 
between the minor G allele at this particular locus, and increased ADR risk, which is 
consistent with our hypothesis.  However, the presence of the same G allele in an individual’s 
genotype was shown to provide some protection from frailty and multi-morbidity, which 
appears to be at odds with the previous finding.   
 
In light of these data, we might therefore want to ask: what effect does the presence of the 
rs35652124 G allele have on Nrf2 gene expression and functionality.  In fact, there is 
conflicting data regarding the influence of the rs35652124 SNP on Nrf2 expression.  Yu et al. 
(2012) compared luciferase activity and Nrf2 mRNA expression at all 3 loci in the promotor 
region and showed a significant reduction in Nrf2 gene expression for the rs35652124 G 
allele.  Marczak et al. (2012) showed that under conditions of oxidative stress, the G allele 
showed decreased Nrf2 expression compared to the A allele (17).  Conversely, Song et al. 
(2016), demonstrated significantly increased luciferase activity with the minor G allele insert 
compared to the major A allele (33).  Both Marzec et al. (2007) and Ran et al. (2016) showed 
a minimal effect of the -653 SNP on luciferase activity and mRNA expression respectively 
(17, 34) under basal conditions.   It is unclear why such differences in the effect of the 
rs35652124 SNP exist – both Yu et al. and Song et al. used the same cell type (human 
embryonic kidney 293 T cells) for their expression assays.  However, it may be the case that 
cell culture conditions, and exposure to stressors play an important role in vitro.  
Furthermore, in vivo (patients), it may be the case that the rs35652124 SNP behaves 
differently in different tissue types according to which transcription factors are expressed.  A 
number of studies have reported that the Nrf2 promoter region is a target for several 
transcription factors (TFs), including Nrf2 itself.  Some of these TFs may bind preferentially 
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to the A allele variant, and others (expressed in different tissues) to the G allele, resulting in 
different expression patterns throughout the human body.   
 
If, however, we take the view that the rs35652124 G allele is associated with decreased Nrf2 
expression, one other possible explanation for the increased risk of multi-morbidity and 
frailty associated with the AA genotype, is that elevated Nrf2 levels are pathogenic for some 
diseases.  Indeed, Nrf2 knockout mice show reduced atherosclerotic plaque area compared to 
controls (35).  Furthermore, in humans the rs35652124 AA genotype is associated with 
significantly increased risk of high blood pressure and cardiovascular mortality (36).  It could 
therefore be the case in our study that the higher multi-morbidity and frailty scores are driven 
by cardiovascular pathology. 
 
In conclusion, we have shown that rs35652124 genotype is a contributory factor to frailty, 
multi-morbidity and the risk of ADR in later life.  Whilst the G variant is a marker of ADR 
risk, it is paradoxically associated with a lower risk of multi-morbidity.  Although our sample 
population was not necessarily reflective of the entire PRIME study cohort, it does offer an 
important insight in to the role Nrf2 plays in the ageing phenotype in humans.  However, 
further work needs to be conducted to determine the generalisability of these results.  
Additionally, experiments should be conducted to establish whether Nrf2 expression and 
downstream phase I and phase II enzyme expression are altered in carriers of the rs35652124 
A allele, and also whether genotype can improve current models that aim to predict ADR, 
frailty and multi-morbidity risk. 
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Gene Direction Reaction type Sequence 
Nrf2 Forward 
Reverse 
q-rtPCR 5′-GAGAGCCCAGTCTTCATTGC-3′  
5′-TGCTCAATGTCCTGTTGCAT-3′ 
GAPDH* Forward 
Reverse 
q-rtPCR 5’-ACCCACTCCTCCACCTTTGAC-
3′  
5’-TCCACCACCCTGTTGCTGTAG-
3′ 
18s ribosomal 
subunit* 
Forward 
Reverse 
q-rtPCR 5’-GTAACCCGTTGAACCCCATT-3′  
5’-CCATCCAATCGGTAGTAGCG-
3′ 
Nrf2 Forward 
Reverse 
PCR / Sanger sequencing 5’ 
CTTTTATCTCACTTTACCGCCC 
3’ 
  
Table 1.  Primer sequences for q-rtPCR, and PCR / Sanger sequencing of Nrf2 gene.  
*Housekeeping genes 
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Age 
category 
(years) 
Proportion 
female (n) 
Chronic 
medical 
condition 
(n) 
Consume 
regular 
medication 
(n) 
Regular 
smoker 
(n) 
Median units 
of EtOH 
consumed 
weekly 
Median age 
(range) 
18-29 15/27 4/27 6/27 3/27 3 (0-16) 22(18-28) 
30-39 3/8 4/8 5/8 2/8 0 (0-15) 33.5 (30-38) 
40-49 6/7 4/7 2/7 1/7 4 (0-10) 42 (41-47) 
50-59 5/9 6/9 5/9 1/9 6 (0-10) 53 (50-57) 
60-69 1/2 2/2 2/2 0/2 8 (6-10) 62 (60-64) 
≥70 0/2 2/2 2/2 0/2 8.75 (7-10.5) 73.5 (72-75) 
Sig. p=0.2955 p=0.0045** p=0.0292* p=0.8802 p=0.2024  
 
Table 2. Demographics of volunteers for according to age-category.  Differences between 
age-groups were tested using Kruskal-Wallis test for continuous, non-parametric data, or the 
Chi2 test for categorical data. 
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 Median (range) 
Age 75.5 (65-92) 
Female (%) 62 (55.4%) 
Number of co-morbidities 3 (0-9) 
Charlson index 1 (0-5) 
Number of regular medicines 7.5 (1-19) 
Frailty index 0.091 (0-0.29) 
 
Table 3.  Demographics of patients enrolled from sub-population of the PRIME study. 
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  rs6721961 
(-617) 
 rs35652124 
(-653) 
 rs6706649 
(-651) 
Frequency of 
genotypes and 
alleles (%) 
AA 0 (0%) AA 45 (40%) AA 2 (2%) 
AC 9 (8%) AG 61 (55%) AG 8 (7%) 
CC 103 (92%) GG 6 (5%) GG 102 (91%) 
A 9 (4%) A 151 (67%) A 12 (5%) 
C 215 (96%) G 73 (33%) G 212 (95%) 
Hardy-Weinberg  p>0.05  p<0.05*  p<0.05* 
 
Table 4.  Genotype and allelic frequencies for the three single nucleotide polymorphisms 
studied.  Deviation from Hardy-Weinberg equilibrium was considered if the observed 
frequencies of genotypes differed significantly (p<0.05 by Fisher’s exact test) from the 
expected frequencies, based on the frequencies of alleles observed in the sample population. 
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Naranjo algorithm: ADR=definite/probable/possible 
 ADR No ADR Frequency 
ADR 
Sig. (Chi2) 
rs35652124 (-653)     
AA 14 31 0.31 p=0.031* 
AG 19 42 0.31  
GG 5 1 0.83  
rs6721961 (-617)     
CC 35 68 0.34 p=0.969 
CA 3 6 0.33  
rs6706649 (-651)     
GG 35 67 0.34 p=0.770 
GA 2 6 0.25  
AA 1 1 0.50  
Naranjo algorithm: ADR=definite/probable 
 ADR No ADR Frequency 
ADR 
Sig. (Chi2) 
rs35652124 (-653)     
AA 7 38 0.15 p=0.137 
AG 12 49 0.20  
GG 3 3 0.50  
rs6721961 (-617)     
CC 21 103 0.20 p=0.502 
CA 1 8 0.11  
rs6706649 (-651)     
GG 19 83 0.19 p=0.502 
GA 2 6 0.25  
AA 1 1 0.50  
 
Table 5.  ADR frequency according to genotype.  An ADR has been classified if it scored as 
definite/probable/possible (top half of table), or definite/probable (bottom half of table) 
according to the Naranjo algorithm.   
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Figure legends 
 
Figure 1. Changes to Nrf2 gene expression and protein levels with age in healthy volunteers.  
A Log Nrf2 mRNA abundance vs. age (n=55) and B Log-fold Nrf2 mRNA change compared 
to 18-29 year-olds (n=55).  B Changes to Nrf2 protein levels with age in heathy volunteers 
(n=30).  *p<0.05 (Student’s t-test), ****P<0.0001 (One-way ANOVA). 
 
Figure 2. Association of the rs35652124 SNP with Co-morbidities (A), Charlson Index (B), 
and Frailty (C) across the whole PRIME sub-population, and those aged between 65-79 years 
old.  *p<0.05, **p<0.01, Mann-Whitney U-test; data are presented as median, 25-75 
percentiles and range. 
